Brief: Nanobiotix Reports Encouraging Full Phase 1 Results For Lung Cancer Drug JNJ-1900
BRIEF-Nanobiotix Reports Encouraging Full Phase 1 Results For Lung Cancer Drug JNJ-1900 Sept 14 (Reuters) - Nanobiotix SA NANOB.PA:
NANOBIOTIX ANNOUNCES COMPLETE FULL COHORT PHASE 1 RESULTS FOR JNJ-1900 (NBTXR3) IN INOPERABLE, RECURRENT NON-SMALL CELL LUNG CANCER
ENROLLMENT IN DOSE-ESCALATION AND EXPANSION PARTS OF STUDY IS COMPLETE PER PROTOCOL
FOLLOWING ENCOURAGING FINDINGS, ADDITIONAL PATIENT ENROLLMENT IN THIS STUDY IS PLANNED
ALL 24 PATIENTS COMPLETED JNJ-1900 (NBTXR3) TREATMENT WITH NO DOSE-LIMITING TOXICITIES OR GRADE 3+ ADVERSE EVENTS
GRADE 3 RADIOTHERAPY-RELATED ADVERSE EVENTS IN 33%, GRADE 5 IN 8%; PHASE 2 DOSE SET AT 33% GROSS TUMOR VOLUME
INVESTIGATORS CONCLUDED THAT JNJ-1900 (NBTXR3) MAY PERMIT CLINICALLY MEANINGFUL LOCAL CONTROL USING A SUBSTANTIALLY LOWER RE-IRRADIATION DOSE
AT 12-MONTH FOLLOW-UP (AUG 2026), ONE-YEAR LOCOREGIONAL CONTROL RATE WAS 79%, LOCAL PROGRESSION-FREE SURVIVAL (LPFS) 61%, OVERALL SURVIVAL (OS) 70%
Source text: ID: nGNE2QXBMG
Further company coverage: NANOB.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00; ))
Recent news on Nanobiotix SA
See all newsBrief: Nanobiotix S.A. H1 Net Income EUR -34.3 Million
France's Nanobiotix H1 net loss widens on lower revenue, absence of 2025 one-off gain
Brief: Nanobiotix Reports Encouraging Full Phase 1 Results For Lung Cancer Drug JNJ-1900
Brief: Nanobiotix Q1 Cash And Cash Equivalents Of €42.1 Mln
Brief: NANOBIOTIX Announces Closing Of Global Offering